We are lipid biology experts focusing on developing novel therapeutics for patients with lipid related disorders. Lipigon develops pharmaceuticals that are first- or best-in-class. Unrestricted by technological approach Lipigon addresses unmet medical needs in the field of lipid disorder driven metabolic disease; e.g. indications in the cardiometabolic space and liver diseases such as NASH/NAFLD. Our primary focus is rare orphan lipid driven disorders where we have two active programs for various dyslipidemias and lipodystrophy.
Our mission is to develop safe and efficient treatments for lipid related disorders in the orphan disease space where no or few approved treatments exist; thus, making a significant improvement in the quality of life and survival of these patients.
Our vision is to build a sustainable research-based company with an innovative pipeline of product candidates in pre-clinical and clinical development. We want to be the world-leading company in the orphan space of lipid-related diseases and the most attractive collaboration partner for broader indications relating to lipid disturbances.
Location: Sweden, Umeå
Employees: 1-10
Founded date: 2010
Investors 3
| Date | Name | Website |
| - | Almi Inves... | almi.se |
| - | Fort Knox | fort-knox.... |
| - | Umeå Biote... | ubi.se/ |